Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer

Published:2024-04 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lu Shun^ORCID,Zhou Qing,Liu Xiaoqing,Du Yingying^ORCID,Fan Yun,Cheng Ying^ORCID,He Shan^ORCID,Zhao Huadong,Li Heyan,Wu Yi-Long^ORCID

Funder

Pfizer Inc

Publisher

Elsevier BV

Reference26 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Lung cancer incidence and mortality in China: updated statistics and an overview of temporal trends from 2000 to 2016;Zheng;JNCC,2022

3. Lung cancer: epidemiology, etiology, and prevention;Dela Cruz;Clin Chest Med,2011

4. Cancer.Net. Lung cancer—non-small cell: statistics. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. 2023. Updated March 2023. Accessed September 2023.

5. Anaplastic lymphoma kinase-special immunity and immunotherapy;Guo;Front Immunol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP